🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rebecca Shatsky

UC San Diego Health System

ORCID: 0000-0003-2289-6234

Also affiliated with University of California San Diego, University of California San Diego Medical Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.918Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine

JCO Precision Oncology(2022)10.1200/po.20.00508
Top 22%
0.918DataRank
Top 22%17 citations

Ramez N. Eskander, Jason K. Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +8 more

Papers

Driven by 14 papers — median percentile 78. Top paper: “Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial”.

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1
N/A
1.4DataRank · unranked
43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine

JCO Precision Oncology(2022)10.1200/po.20.00508
Top 22%
0.918DataRank
Top 22%17 citations

Ramez N. Eskander, Jason K. Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +8 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009
N/A
0.873DataRank · unranked
337 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Nature Communications(2020)10.1038/s41467-020-18613-3
N/A
0.859DataRank · unranked
305 citations

Ki Hwan Kim, Hyo Jeong Lim, Amélie Boichard, Mina Nikanjam, Elizabeth Weihe +17 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2
N/A
0.610DataRank · unranked
13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Annals of Oncology(2024)10.1016/j.annonc.2024.10.018
N/A
0.494DataRank · unranked
26 citations

David S. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Claudine Isaacs +15 more

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06914-2
N/A
0.441DataRank · unranked
7 citations

Rebecca Shatsky, Richard B. Schwab, Anne M. Wallace, Denise M. Wolf, Gillian L. Hirst +7 more

Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.591
N/A
0.292DataRank · unranked
6 citations

Rebecca Shatsky, Christina Yau, Denise M. Wolf, Rita Nanda, L. J. van ‘t Veer +4 more

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

Nature Communications(2025)10.1038/s41467-025-65432-5
N/A
0.292DataRank · unranked
6 citations

Nayelis A. Manon, Denise M. Wolf, Samuel Rivero-Hinojosa, Ziad Ahmed, Rosalyn W. Sayaman +20 more

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba612
N/A
0.165DataRank · unranked
2 citations

Alexandra Thomas, Christina Yau, A. Jo Chien, Carla I. Falkson, Erica Stringer-Reasor +15 more

Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.510
N/A
0.104DataRank · unranked
1 citations

Amy S. Clark, Christina Yau, Denise M. Wolf, L. J. van ‘t Veer, Emily Douglas +10 more

Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

Annals of Surgical Oncology(2025)10.1245/s10434-025-17864-y
N/A
0.104DataRank · unranked
1 citations

Katrina Dimitroff, Judy C. Boughey, Laura J. Esserman, Christina Yau, Julia Tchou +34 more

Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.10600
N/A
0DataRank · unranked
0 citations

Pooja Middha, Zoe Quandt, Yiwey Shieh, Amrita Basu, Rosalyn W. Sayaman +11 more

Racial and ethnic disparities among patients with breast cancer and COVID-19.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6500
N/A
0DataRank · unranked
0 citations

Melissa Accordino, Benjamin French, Nicole M. Kuderer, Gary H. Lyman, Daniel G. Stover +14 more